Consumer Health Cancer / Immunology
Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisi...
May 31, 2023 | News
Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...
May 31, 2023 | News
ORSERDU (elacestrant) was approved by the FDA in January 2023 for advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor (...
May 30, 2023 | News
Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic ...
May 30, 2023 | News
Proteomedix, a Swiss diagnostics company committed to advancing prostate cancer care, announced today that it entered into an agreement for Labcorp, a...
May 22, 2023 | News
With this qualification, Discovery gains access to Akoya's PhenoImager® HT workflows, which can provide insights into the tumor microenvironment (...
May 19, 2023 | News
Under the agreement, Asieris Pharmaceuticals will use this patented technology in combination with specific optical imaging agents to conduct research on t...
May 19, 2023 | News
Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evalua...
May 17, 2023 | News
Hummingbird Bioscience enters a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001, a potentially best-in-class anti-HER3 ...
May 16, 2023 | News
This BTD for IBI351 was based on the pooled analysis of two ongoing clinical trials (NCT05005234, NCT05497336), which include 54 CRC pa...
May 15, 2023 | News
LaNova Medicines Ltd. ("LaNova Medicines") announced it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305,...
May 15, 2023 | News
CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary techno...
May 11, 2023 | News
Sonelokimab is MoonLake Immunotherapeutics' investigational anti-IL-17 A/F Nanobody technology designed to more directly target sites of inflammation and p...
May 11, 2023 | News
Increasing localized access can provide faster results for patients while potentially improving patient outcomes Agreement aims to enable greater access t...
May 10, 2023 | News
Most Read
Bio Jobs
News
Editor Picks